INVO Fertility, Inc. (IVF) is a micro-cap healthcare company on the Nasdaq Capital Market that builds, acquires, and operates fertility clinics and sells its INVOcell medical device. After a series of reverse stock splits and a deep selloff, the shares have tumbled into sub-dollar territory, and a key question for traders is whether the stock can claw its way back to the $1.00 level. That target is not an analyst consensus; it reflects Nasdaq's minimum bid price requirement and a round-number psychological threshold.
IVF does not have a meaningful, current analyst consensus. The most recent clearly attributable rating is a Buy from Maxim Group with a $4.00 price target issued on February 10, 2026. That call was made before the company's 1-for-5 reverse split in March 2026 and before the stock's subsequent decline, so it offers limited guidance for today's sub-dollar price. Aggregators show divergent figures — MarketWatch lists a single $4.00 target, while others display $20.00 — a spread that most plausibly reflects mechanical reverse-split adjustments rather than several independent, current forecasts. Because fewer than two credible, current targets exist, no reliable average analyst price target can be calculated, and the $1.00 level is used instead as a market-structure objective drawn from Nasdaq's listing rules and public discussion of the company's compliance challenges.
The shares have fluctuated roughly between $0.64 and $1.00 in recent weeks, with a mid-October 2026 close near $0.64, reflecting extraordinary volatility. Reaching $1.00 from that level implies a roughly 56% gain — a substantial move. A path toward it would most likely run through a stabilization of the share price, renewed institutional or retail interest, and concrete progress on the company's finances and regulatory filings. INVO Fertility generates modest revenue (about $7.5 million trailing) but remains unprofitable, and it has delayed its annual 10-K filing citing tax-related review delays, which has weighed on confidence.
A rebound toward $1.00 could be supported by restored Nasdaq compliance, an improvement in the company's cash position, or evidence that its fertility clinic model is moving toward profitability. The company's strategic focus narrowed in 2025 to fertility care after divesting its oncology operations, which simplified the business. Its INVOcell device offers a lower-cost alternative to traditional in vitro fertilization, a positioning that could appeal to value-conscious patients. Any positive developments in filings, financing, or clinic-level margins could help sentiment recover.
The obstacles are substantial. The company is unprofitable and has relied on repeated reverse stock splits to maintain its Nasdaq listing, a pattern that has eroded shareholder value. The delayed 10-K filing introduces accounting and governance uncertainty. Micro-cap fertility names face intense competition from larger, better-capitalized clinic operators, and a sub-$1 share price heightens delisting risk. Sustained selling pressure, dilution, and weak fundamentals could keep the stock below $1.00 or drive it lower.
$1.00 is both a psychological round number and the Nasdaq minimum bid threshold, making it the most durable nearby level to watch. Trading below it places the shares in penny-stock territory with associated compliance risk. Above that, the stock's post-split reference points — including the roughly $2.68 level recorded around the March 2026 reverse split — represent further resistance. The long-term structure remains a downtrend, marked by deep drawdowns and reduced trading liquidity.
Because the $1.00 target is a compliance and technical milestone rather than an analyst target, no specific 12-month horizon applies. Investors should monitor the company's next earnings releases, the resolution of the delayed annual report, any financing or dilution announcements, and Nasdaq compliance communications. Nasdaq delisting notices, further reverse splits, or new capital raises would be decisive for the stock's near-term direction.
Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs and generate Buy, Sell, or Hold signals as market conditions evolve. The system analyzes technical behavior and AI-driven data to help traders discover opportunities, track positions, and spot changing trends more efficiently than manual screening. For a volatile micro-cap such as IVF, where moves can be sharp and sentiment-driven, a systematic signal layer can help separate short-term noise from genuine directional shifts. Traders can explore the AI Daily Buy/Sell Signals page to see how these automated insights apply to their own watchlists.
Can INVO Fertility (IVF) reach $1.00? The target is achievable in principle but requires a substantial — roughly 56% — recovery from recent levels, against a backdrop of continued losses, a delayed filing, and a history of reverse splits. There is no reliable analyst consensus to lean on; the single dated Maxim Group target of $4.00 offers little help for today's price. The clearest catalysts are Nasdaq compliance, financing, and any sign of progress toward profitability, while dilution and delisting risk remain the principal threats. Investors should watch the next filings and earnings updates closely rather than relying on any single forecast.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, IVF has been loosely correlated with VNDA. These tickers have moved in lockstep 40% of the time. This A.I.-generated data suggests there is some statistical probability that if IVF jumps, then VNDA could also see price increases.
| Ticker / NAME | Correlation To IVF | 1D Price Change % | ||
|---|---|---|---|---|
| IVF | 100% | +6.38% | ||
| VNDA - IVF | 40% Loosely correlated | -0.24% | ||
| IVA - IVF | 30% Poorly correlated | +2.86% | ||
| RANI - IVF | 30% Poorly correlated | -2.47% | ||
| IRD - IVF | 27% Poorly correlated | +0.71% | ||
| KPTI - IVF | 26% Poorly correlated | -56.50% | ||
More | ||||
| Ticker / NAME | Correlation To IVF | 1D Price Change % |
|---|---|---|
| IVF | 100% | +6.38% |
| Medical/Nursing Services industry (138 stocks) | 6% Poorly correlated | -1.46% |
| Health Services industry (239 stocks) | 3% Poorly correlated | -1.13% |